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ABSTRACT  
A dissolution method was developed and UV spectrophotometry was developed for the evaluation of the dissolution of tablets containing 15 mg 
Noscapine .The dissolution medium 0.1 N HCl was found suitable to ensure sink conditions. USP Apparatus 2, 900 mL dissolution medium 45 
minutes and 100 RPM were fixed. Dissolution profiles were generated at 10, 15, 20,   30; 45 min. Dissolution samples were analyzed with UV 
spectrophotometer at 213 nm. The UV method for determination of tablet was developed and validated. The method presented linearity (R2 = 
0.999) in the concentration range of 1–9 μg/mL. The recoveries were good, ranging from 97.18% to 101.45%. The intraday and Interday 
precision results were 0.54% and 0.78% RSD, respectively. The developed dissolution test is adequate for its purpose and can be applied for the 
quality control of tablets. 
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INTRODUCTION  
Dissolution is defined as the rate and extent in which the 
amount of drug substance dissolved over a period of time. It 
is expressed as percentage release of drug substances 
present dosage forms like Tablets, Capsules, ointments and 
oral suspensions.[1] In the present study dissolution method 
was developed for immediate release tablet(15 mg 
Noscapine). 
The dissolution method developed for tablets is to evaluate 
the release pattern. [2] 
 In vitro dissolution tests for immediate release solid oral 
dosage forms are used: (a) to assess the lot-to-lot quality of a 
drug product;  
(b) To assess the stability of the drug product;  
(c) To ensure continuing product quality and performance 
after certain changes, such as changes in the formulation, the 
manufacturing process, the site of manufacture, and the 
scale-up of the manufacturing process; and 
 (d) To develop new formulations. In formulation 
development, dissolution testing can aid in the selection of 
excipients, help optimize the manufacturing process, and 
enable formulation of the test product to match the release 
of the reference product [3] 
For immediate release products the basket (apparatus 1, 
usually at 100 rpm) and paddle (Apparatus 2, usually at 50 
to 75 rpm) are conventional. Immediate release means 75% 
of the API is dissolved within 45 minutes, while the term 
rapidly dissolving means 85% API dissolved in 30 minutes 
and very rapidly dissolving 85% API in dissolved 15 minutes 
are important in dissolution testing. 
Different Medias should be considered for immediate release 
products during development studies which are following: 
• PH 1.2 buffer or 0.1 M Hydrochloric acid. 
• pH 4.5 buffer 
• pH 6.8 buffer 
• Water may be considered as an additional medium 
For development purposes the generation of dissolution 
patterns at short intervals such as 10, 15, 20, 30 and 45 
minutes in the above media are recommended. [2] 
The validation of the dissolution test can be divided into two 
parts.  
• Equipment validation; equipment has to be calibrated 
taking into consideration the specifications for 
geometry and alignment of the dissolution apparatus.  
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• Test validation and requires the study of the 
performance parameters like accuracy, precision, 
robustness 
 It is true that a more discriminating dissolution method is 
preferred, but it is also true that a reliable dissolution test is 
of utmost importance.  
 A dissolution test with good precision makes it possible to 
efficiently compare several alternative formulation 
candidates to select the dosage form with the most suitable 
and reproducible drug release profile. [4] 
Following are the parameters that are usually considered 
during method development for Dissolution.  
• Selection of dissolution medium 
Selection of dissolution medium depends upon following 
parameters. 
a. Type of formulation (Immediate release or modified 
release). 
b. Solubility characteristics of active component. 
c. Type formulation design, (Tablets, Oily suspension, Soft 
gel capsule, hard gel capsule, etc.) 
• Selection of RPM  
Apparatus, Type of formulation and solubility characteristics 
of active substances are parameters which are used for 
selection of RPM 
 Any change in apparatus and use of higher RPM other than 
recommended parameters should be justified.  
• Selection of dissolution time interval  
Dissolution time is defined as the time in minutes at which 
maximum amount (+80% of label claim) of drug is dissolved. 
For immediate release dosage forms, 30min. to 60min. is 
recommended as dissolution time.  
In some cases dissolution time may be higher i. e. up to 
90min to 120min.  
In such cases suitable justification should be provided. For 
modified release formulations (delayed release, enteric 
coated and sustained release), time depends upon design of 
formulation, site of action and therapeutic use.  
Time for such formulations may be from about 6 hrs to 24 
hrs or may be higher. 
• Selection of other parameters  
Media volume: 
 The volume of dissolution media is ideally 900ml, however 
if label claim is less than 5mg and if active substances has 
less absorbance at selected wavelength, then in that case 
dissolution volume can be reduced to 500ml.  
Media temperature: 
The dissolution media temperature is fixed (i. e. 37.0 ºC) [4] 
Introduction to drug  
Noscapine is (3S)-6,7-Dimethoxy-3-[(5R)-4-methoxy-6-
methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-
yl]isobenzofuran-1(3H)-one (Figure 1). It is practically 
insoluble in water but soluble in organic solvents like in 
acetic acid (100), Ethanol (95) and in diethyl ether. It is 
centrally acting Antitussive. [5-8] Noscapine inhibit 
bradykinin as the mode by which it functions. Noscapine’s 
effect in treating strokes has been attributed to its 
Bradykinin suppressive effect and its anti-cancer effect has 
been primarily attributed to its Microtubuleinterfering 
effect. [9]  
 
[MW=413.42 g/mol, chemical structure: C 22H23NO7] 
 
MATERIALS AND METHODS 
Noscapine reference standard (99.947%) and noscapine 
tablets (containing 15 mg Noscapine) were kindly given by 
Bharat Parenterals Pvt. Ltd, Haripura, and Savli. 
 Analytical reagent grade, Hydrochloric acid, anhydrous 
potassium hydrogen phosphate, sodium hydroxide were 
used. Freshly distilled water was used throughout the study. 
Phosphate buffer pH 6.8, Phosphate buffer pH 4.0, 0.1 N HCl 
was prepared according to USP 27. 
Apparatus 
The dissolution test was performed in a six-station 
Electrolab dissolution tester in accordance with USP 27 
general methods. A Shimadzu UV–vis spectrophotometer 
(model UV–1800) using 1.0-cm quartz cells and UV probe 
software were used for all absorbance measurements. A 
digital pH meter was used to determine the pH of all 
solutions. The ultrasonic bath used for deaeration. 
Selection of Dissolution Media 
Solubility data were used as the basis for the selection of a 
dissolution medium for Noscapine. 
Quality Control Testing of 15-mg Noscapine Tablets 
Noscapine tablets containing 15 mg of Noscapine were 
evaluated for color, shape, size, weight, variation, friability, 
disintegration time, hardness, drug content, and content 
uniformity. 
Optimization of Dissolution method 
The dissolution experiments were conducted in a six-station 
bath dissolution apparatus by adding Noscapine tablet (n=6) 
in bowl of 900 mL of each dissolution medium, a paddle 
dissolution apparatus, and stirring speeds of 50, 75, and 100 
RPM. The temperature was stabilized at 37 ± 0.5 ° C. 
Aliquots of 10 mL were withdrawn manually at 45 min. The 
same volume of medium at 37 ± 0.5 ° C was replaced for 
constant volume. The sample was filtered through Whatman 
No. 41 filter paper and analyzed spectrophotometrically at 
213 nm. The standard solution used in all dissolution tests 
was prepared using Noscapine equivalent to 15 mg. The UV 
spectrophotometric method was developed and validated. 
Validation of Dissolution Method  
The method was validated by the analysis of specificity, 
linearity and range, accuracy, precision (intermediate 
precision and repeatability) and robustness (change in 
analyst, laboratory, instrument). 
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Specificity 
A placebo sample of the reference formulation of tablets in 
the usual concentration of excipients was prepared to 
demonstrate reliability and reproducibility of the method. 
The placebo sample was transferred to vessels containing 
900 mL of dissolution medium and stirred at 37 °C for 45 
minute at 100 RPM using a paddle apparatus. Aliquots of the 
solutions were filtered through filter paper (Whatman No. 
41) and analyzed by UV spectrophotometric method. [10] 
Linearity: Aliquots of Noscapine stock solution (100 μg/mL) 
were diluted with 0.1 N HCl to give concentrations of 1–9 
µg/mL (n=5). [11-14] 
Accuracy: 
The recovery study was performed using Noscapine tablets. 
Noscapine reference substance was added to the dissolution 
vessels in known amounts at the 80%, 100%, and 120% 
levels.12, 15, and 18 mg of Noscapine reference standard 
respectively was added along with each 15-mg Noscapine 
tablet. The dissolution test was performed on Noscapine 
tablets for 45 min using 900 mL of 0.1 N HCl as medium in a 
paddle apparatus at 100RPM. Aliquots of 10 mL were 
filtered through filter paper (Whatman No. 41) and analyzed 
by developed UV spectrophotometric method at the spiked 
concentration levels of 80%, 100%, and 120%, respectively. 
Each concentration was analyzed in triplicate. [11-14]
 
Table 1: Accuracy data for dissolution method 
Tablet 
amount 
Level of 
addition (%) 
Amount  
added (mg) 
Absorbance Total 
amount 
Amount 
recovered (mg) 
% 
Recovery 
Average % 
recovery 
- 0 - 0.254 1.49 - - - 
- 0 - 0.257 1.51 - - - 
- 0 - 0.255 1.50 - - - 
15 mg  12 0.423 2.69 11.89 99.09 99.48779 
15 mg 80 12 0.427 2.72 12.17 101.45 
15 mg  12 0.421 2.68 11.75 97.91 
15 mg  15 0.467 3.01 15.01 100.07 98.50276 
15 mg 100 15 0.463 2.97 14.73 98.18 
15 mg  15 0.461 2.96 14.58 97.24 
15 mg  18 0.507 3.29 17.85 99.15 98.37142 
15 mg 120 18 0.506 3.28 17.78 98.76 
15 mg  18 0.502 3.25 17.49 97.18 
 
Precision 
Repeatability was determined by analyzing six samples of 
Noscapine tablets with the optimized dissolution test. 
Aliquots were collected and evaluated by the UV method at 
213 nm. Thus, repeatability was evaluated with the relative 
standard deviation (RSD) of the data at the 100% level. 
The evaluation of intermediate precision was performed 
using Noscapine tablets. The intermediate precision was 
determined on different time on same day (intraday) and 
different days (Interday) and the RSD values were 
calculated. The dissolution test was performed on six 
Noscapine tablets for 45 min using 900 mL of 0.1 N HCl as 
dissolution medium in Apparatus 2 at 100 RPM. Aliquots of 
10 mL were filtered with quantitative filter and analyzed by 
the UV spectrophotometric method. Each concentration was 
analyzed in triplicate. [11-14] 
 
Table 2: Dissolution Release Rate of Noscapine Tablets in0.1 N HCl, Paddle Apparatus, 100 rpm 
Sr 
No. 
10 
minute 
% drug 
dissolved 
15 
minute 
% drug 
dissolved 
20 
minute 
% drug 
dissolved 
30 
minute 
% drug 
dissolved 
45 
minute 
% drug 
dissolved 
1 0.097 33.10 0.189 64.50 0.258 88.05 0.299 102.04 0.301 102.73 
2 0.098 33.44 0.197 67.23 0.201 68.60 0.275 93.85 0.278 94.88 
3 0.115 39.24 0.177 60.40 0.238 81.22 0.302 103.07 0.306 104.43 
4 0.109 37.20 0.199 67.91 0.255 87.03 0.287 97.95 0.291 99.31 
5 0.112 38.22 0.184 62.79 0.221 75.42 0.296 101.02 0.298 101.70 
6 0.118 40.27 0.173 59.04 0.234 79.86 0.273 93.17 0.278 94.88 
 
Robustness 
The robustness was tested by changing several parameters 
of the dissolution method subsequently, equipment, analyst 
and laboratory. The dissolution test was performed on six 
Noscapine tablets for 45 min using 900 mL of 0.1 N HCl as 
medium in Apparatus 2 at 100 RPM in different laboratories, 
with two different analysts and with two different analytical 
instruments in the same laboratory.  Aliquots of 10 mL were 
filtered and analyzed by the UV method. The dissolution data 
were compared with the initial data. [11-14] 
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RESULTS AND DISCUSSION 
Determination of Solubility: As Noscapine is not soluble in 
water and phosphate buffer pH6.8, distilled water and 
phosphate buffer pH6.8 were not selected   for media has 
solubility in 0.1 N HCI so, it was selected for media 
Quality control test results of 15-mg Noscapine tablets 
containing Noscapine complied with IP specifications. 
(Results not reported.) 
Mechanical Calibration of Dissolution Apparatus 
Dissolution apparatus was calibrated as per guidelines. [14, 15] 
Optimization of Dissolution method 
0.1 N hydrochloric acid is suitable dissolution media. The 
results of the dissolution study are depicted in Figures.  
Dissolution of drug from a dosage form involves two 
consecutive steps, liberation of the drug from the 
formulation matrix which is disintegration followed by 
dissolution of                
The  drug which is solubilization of the drug particles in the 
dissolution medium.   
The optimum dissolution conditions for the assessment of 
release were 900 mL of 0.1 N HCl at 37 °C as the dissolution 
medium, paddle apparatus at a stirring speed of 100  
RPM and 45 min as collection time. 
Specificity 
When the placebo tablets were subjected to the dissolution 
test and analyzed, the absorbance was equivalent to 1.71 % 
of Noscapine tablet concentration. According to ICH 
guidelines, the dissolution method is specific if the 
interference is not more than 2%. The dissolution method 
was specific. 
Linearity 
For Assessing linearity, a standard curve for Noscapine was 
constructed by plotting average absorbance versus 
concentration. The linearity was evaluated by linear 
regression analysis. The curves show good linearity in the 
range of 1–9 µg/mL. The line equation was y = 0.141x + 
0.043 with a slope of and R² = 0.999. The RSD for each point 
was less than 2%. These data indicate that the method is 
linear for Noscapine within the specification limits. 
 
Sr. 
No. 
Concentration 
(μg/mL) 
Abs (mean  ± SD) 
(n = 5) 
% RSD 
1 1 0.192 ± 0.0029 1.54 
2 3 0.468 ± 0.0029 0.62 
3 5 0.738 ± 0.0032 0.44 
4 7 1.015 ± 0.0130 1.30 
5 9 1.330 ± 0.0053 0.40 
 
Accuracy 
The accuracy expresses the agreement between the accepted 
value and the observed value. The recovery for a dissolution 
test must be in the range of 95–105%, according to ICH 
guidelines. The percent recovery was from 96.407% to 
100.24%. The accuracy of the method is acceptable.
 
Table 3: 
Tablet 
amount 
Level of 
addition (%) 
Amount  
added (mg) 
Absorbance Total 
amount 
Amount 
recovered (mg) 
% 
Recovery 
Average % 
recovery 
- 0 - 0.254 1.49 - - - 
- 0 - 0.257 1.51 - - - 
- 0 - 0.255 1.50 - - - 
15 mg  12 0.423 2.69 11.89 99.09 99.48779 
15 mg 80 12 0.427 2.72 12.17 101.45 
15 mg  12 0.421 2.68 11.75 97.91 
15 mg  15 0.467 3.01 15.01 100.07 98.50276 
15 mg 100 15 0.463 2.97 14.73 98.18 
15 mg  15 0.461 2.96 14.58 97.24 
15 mg  18 0.507 3.29 17.85 99.15 98.37142 
15 mg 120 18 0.506 3.28 17.78 98.76 
15 mg  18 0.502 3.25 17.49 97.18 
 
 
 
 
 
 
y = 0.1412x + 0.0431 
R² = 0.9991 
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Precision: 
6.10.4(a) Repeatability 
Table 4: Repeatability data for dissolution method 
Sr. No. Absorbance % Drug dissolved 
1 0.287 97.95 
2 0.288 98.29 
3 0.289 98.63 
4 0.287 97.95 
5 0.287 97.95 
6 0.288 98.29 
 Average 98.17 
 SD 0.278668 
 % RSD 0.283834 
 
6.10.4. (b) intermediate precision 
Table 5: Intraday precision data for dissolution method 
Sample No. T1 T2 T3 
% drug dissolved (mean ± SD) 98.46 ± 1.67 98.00± 1.68 97.49 ± 1.59 
%RSD 1.69 1.71 1.63 
 
Table 6: Interday precision data for dissolution method 
Sample No. Day i Day ii Day iii 
% drug dissolved (mean ± SD) 98.63± 1.93 97.66 ± 1.82 97.32 ±1.81 
%RSD 1.95 1.86 1.86 
 
The percent RSD did not exceed 5% for the repeatability and intermediate (Interday and intraday) precision, demonstrating 
suitable precision. 
Robustness: 
Table 7:   Robustness data (Change in analyst) 
Sr. No. Analyst 1 Analyst 2 
% drug dissolved (mean ± SD) 98.52 ± 1.74 98.40 ± 1.73 
% RSD 1.77 1.763 
 
Table 8: Robustness data (Change in equipment) 
Sr. No. Equipment 1 Equipment 2 
% drug dissolved (mean ± SD) 98.52 ± 1.74 98.23 ± 1.78 
% RSD 1.77 1.81 
 
Table 9: Robustness data (Change in laboratory) 
Sr. No. % Recovery % Recovery 
% drug dissolved (mean ± SD) 98.52 ± 1.74 98.23 ± 1.78 
% RSD 1.77 1.81 
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Table 10: Robustness data (Change in rotation speed, changing normality and volume of dissolution medium) 
Factor Change level(n=3) Average % drug dissolved± SD % RSD 
Rotation speed 98 99.31±2.04 2.06 
100 100.11± 1.38 1.37 
102 100.57±1.19 1.19 
Normality  of 
dissolution medium 
0.09 N 98.75±2.56 2.59 
0.1 N 99.43±1.38 1.38 
0.11 N 100.11±2.27 2.26 
Volume of 
dissolution medium 
890 mL 102.16±0.52 0.51 
900 mL 99.43±0.86 0.86 
910 mL 97.84±0.52 0.52 
 
 
The robustness of the method was demonstrated by 
changing the instrument, the analyst and the laboratory 
(interlaboratory study). The percent RSD   values were 
within the specified limit of 5 % indicating the robustness of 
dissolution method  
CONCLUSION 
The dissolution method was developed and validated for 
Noscapine tablets is satisfactory. The most discriminating 
conditions for dissolution testing of Noscapine tablets (0.1 N 
HCl as a dissolution medium paddle apparatus, stirring speed 
of 100 rpm, and collection time of 45 min) appear to be the 
best conditions. Validation shows that the dissolution test is 
appropriate for quantification of Noscapine in tablet 
pharmaceutical form for in vitro studies, presenting linearity 
and range, specificity, precision (intermediate and 
repeatability), accuracy, and robustness. The method is 
adequate for use in quality control testing of noscapine 
tablets 
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